TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3224001

Group type: EXPERIMENTAL
Intervention: Screening with Lipid Research Clinics Coronary Primary Prevention Trial criteria (≥ 265 mg/dL)
Number of subjects: 10068

Group type: EXPERIMENTAL
Intervention: Screening with National Cholesterol Education Program (NCEP) criteria (≥ 200 mg/dL)
Number of subjects: 10068

Group type: EXPERIMENTAL
Intervention: Screening with NIH Consensus Conference on Lipid Lowering age-related definitions
Number of subjects: 10068

Group type: EXPERIMENTAL
Intervention: Follow-up cholesterol determination for hypercholesterolemia subjects (≥ 265 mg/dL at screening)
Number of subjects: 10068
Study: 29114934

Group type: EXPERIMENTAL
Intervention: Territorial user rights for fisheries (TURFs) system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fisher associations authorizing poaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Government support for enforcement
Number of subjects: 0
Study: 28745999

Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly (162 mg)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Tocilizumab every other week (162 mg)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo with 26-week prednisone taper
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo with 52-week prednisone taper
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly or every other week
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Tocilizumab every other week
Number of subjects: 251
Study: 26287338

Group type: EXPERIMENTAL
Intervention: Ulinastatin group (methylprednisolone + ulinastatin)
Number of subjects: 104

Group type: COMPARATOR
Intervention: IVIG group
Number of subjects: 104
Study: 23773357

Group type: EXPERIMENTAL
Intervention: Micafungin (MCFG) administered intravenously at a dose of 3 mg/kg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fluconazole (FLCZ) administered intravenously at a dose of 5 mg/kg/day
Number of subjects: 39
Study: 21969509

Group type: EXPERIMENTAL
Intervention: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (15 mL phosphate-based buffer) twice per day for a maximum of three 14-week cycles (12 weeks on, 2 weeks off)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral talactoferrin (1.5 g in 15 mL phosphate-based buffer)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (15 mL phosphate-based buffer)
Number of subjects: 100
Study: 18171442

Group type: EXPERIMENTAL
Intervention: Pictorial‐CERT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CR‐10
Number of subjects: 50
Study: 19906454

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 33 × 10(3) IU before PCI, and 24 and 48 hours after admission
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16046344

Group type: EXPERIMENTAL
Intervention: Short term detraining (6 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Long term detraining (52 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Exercise training (9 weeks multicomponent exercise training programme)
Number of subjects: 21
Study: 12193492

Group type: EXPERIMENTAL
Intervention: Alfentanil at a 15 microg x kg(‐1) dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfentanil at a 30 microg x kg(‐1) dose
Number of subjects: 20
Study: 9640850

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM) for six months
Number of subjects: 522

Group type: COMPARATOR
Intervention: Usual care for six months
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management (GEM)
Number of subjects: 522
Study: 8021627

Group type: EXPERIMENTAL
Intervention: Cooperative reward
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individualistic reward
Number of subjects: 0
Study: 3052893

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g i.v. single dose)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Cefazolin (2 g i.v. before surgery and after 8 hours)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 460

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 460
Study: 30346431

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day for 6 months followed by memantine 20 mg/day for responders
Number of subjects: 38

Group type: COMPARATOR
Intervention: Galantamine 16 mg/day for 6 months
Number of subjects: 38
Study: 28615375

Group type: EXPERIMENTAL
Intervention: Diet with 43 g almonds/d
Number of subjects: 48
Study: 26518022

Group type: EXPERIMENTAL
Intervention: Intensive group‐based intervention (52 group sessions and telephone counseling contacts)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Non‐intensive control (two in‐person counseling sessions)
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Intensive group‐based intervention
Number of subjects: 692

Group type: COMPARATOR
Intervention: Non‐intensive control
Number of subjects: 692
Study: 24267093

Group type: EXPERIMENTAL
Intervention: Menadione (MD) as a pre‐column reagent for HPLC analysis of aliphatic thiols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard and placebo solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAC recovery studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine chromatographic separations on a Synergi MAX‐RP column
Number of subjects: 0
Study: 19452271

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS), a cognitive behavioral intervention for women with PTSD and SUD
Number of subjects: 346

Group type: COMPARATOR
Intervention: Women's Health Education (WHE), an attention control psychoeducational group
Number of subjects: 346
Study: 17972276

Group type: EXPERIMENTAL
Intervention: High-dose glycine (0.8 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17542716

Group type: EXPERIMENTAL
Intervention: Survey respondents who had heard of clinical trials (CTs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Survey respondents who had previously been approached to participate in a trial
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Survey respondents who agreed to participate in a trial
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: General findings regarding attitudes towards clinical trials
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Need for education programs
Number of subjects: 100
Study: 12908658

Group type: EXPERIMENTAL
Intervention: Second generation antipsychotics (olanzapine, quetiapine, risperidone, ziprasidone)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Perphenazine (midpotency first generation antipsychotic)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Open-label clozapine or double-blinded second generation drug (available but not assigned in phase 1)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Double-blinded randomization to ziprasidone or another second generation drug (available but not assigned in phase 1)
Number of subjects: 1500
Study: 11092778

Group type: EXPERIMENTAL
Intervention: One-session psychological treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Oral selected midazolam
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 91
Study: 8854297

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1629885

Group type: EXPERIMENTAL
Intervention: Captopril (75 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 6835890

Group type: EXPERIMENTAL
Intervention: 0.45 mg meptazinol/kg/hr
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.3 mg pethidine/kg/hr
Number of subjects: 30

Group type: COMPARATOR
Intervention: pethidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: meptazinol
Number of subjects: 30
Study: 28544170

Group type: EXPERIMENTAL
Intervention: NHEBEF (Nordic hamstring exercises before training)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: NHEAFT (Nordic hamstring exercises after training)
Number of subjects: 35

Group type: COMPARATOR
Intervention: CON (core stability exercises)
Number of subjects: 35
Study: 25944829

Group type: EXPERIMENTAL
Intervention: Home-based educational strategy by community health volunteers (CHVs)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Formal education program using paid health professionals (FHPs)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 231
Study: 25331625

Group type: EXPERIMENTAL
Intervention: ACT-246475 (1,000 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACT-281959 (F2) 70 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACT-246475 (dF) 50 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: ACT-281959 (F1) 70 mg
Number of subjects: 40
Study: 23526240

Group type: EXPERIMENTAL
Intervention: Diclofenac + B vitamins mixture (75 mg sodium diclofenac, 100 mg thiamine, 100 mg pyridoxine, 5 mg cyanocobalamin)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Diclofenac alone (75 mg sodium diclofenac)
Number of subjects: 48
Study: 19663757

Group type: EXPERIMENTAL
Intervention: Lobeline sulfate
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 18756970

Group type: EXPERIMENTAL
Intervention: IL-12 + IL-2
Number of subjects: 50

Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 50
Study: 16814644

Group type: EXPERIMENTAL
Intervention: Overlapping Cypher sirolimus‐eluting stents (SES)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 575
Study: 15247556

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 400/100 mg BID + Phenytoin 300 mg QD (days 11-22)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phenytoin 300 mg QD + Lopinavir/ritonavir 400/100 mg BID (days 12-23)
Number of subjects: 24
Study: 11243418

Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Almotriptan 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Almotriptan 50 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8988349

Group type: EXPERIMENTAL
Intervention: Morning administration of intranasal salmon calcitonin (sCT) 200 IE
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Evening administration of intranasal salmon calcitonin (sCT) 200 IE
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 9
Study: 8500919

Group type: EXPERIMENTAL
Intervention: Test formulation of loxapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of loxapine
Number of subjects: 0
Study: 3481316

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200mg bid for 6 days
Number of subjects: 7
Study: 29423947

Group type: EXPERIMENTAL
Intervention: AXP1275 (50 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 27100717

Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hot Snare Resection
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR) for polyps >20mm
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hot Snare Resection for polyps >20mm
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR) for polyps <19mm
Number of subjects: 104

Group type: COMPARATOR
Intervention: Hot Snare Resection for polyps <14mm
Number of subjects: 104
Study: 25919118

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 30
Study: 23589560

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus carboplatin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin
Number of subjects: 191
Study: 19713947

Group type: COMPARATOR
Intervention: Weight-loss diet (WL) with caloric restriction of 500 kcal/d
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Weight-loss diet plus resistance training (WL+RT) with caloric restriction of 500 kcal/d and 16-week supervised whole body PRT (2 sessions/week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 34
Study: 18439201

Group type: EXPERIMENTAL
Intervention: Consumption of alcohol mixed with energy drinks (AmED)
Number of subjects: 4271
Study: 16770694

Group type: EXPERIMENTAL
Intervention: Nutrition education (group or individual)
Number of subjects: 466
Study: 12814414

Group type: EXPERIMENTAL
Intervention: Short-term pre-operative cessation of smoking, counselling and nicotine replacement therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maintenance of daily smoking habits
Number of subjects: 60
Study: 10403266

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 126
Study: 7587218

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen-progestin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various estrogen and estrogen/progestin regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen and estrogen/progestin therapy
Number of subjects: 0
Study: 2405897

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.0%
Number of subjects: 45
Study: 7441009

Group type: EXPERIMENTAL
Intervention: Clindamycin with gentamicin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Chloramphenicol with gentamicin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ticarcillin with gentamicin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 175
Study: 30994410

Group type: EXPERIMENTAL
Intervention: Telehealth-based health coaching (INT group) with weekly videoconferencing for health coaching and monthly medical monitoring.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Self-guided (CON group) without weekly health coaching.
Number of subjects: 25
Study: 30082170

Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg once daily) combined with oral etoposide (50 mg once daily on days 1-14 of a 21-day cycle)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Apatinib combined with oral etoposide
Number of subjects: 35
Study: 26920573

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Informational pamphlet (IP)
Number of subjects: 30
Study: 24636462

Group type: EXPERIMENTAL
Intervention: Agomelatine 50mg u.i.d.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Melatonin 10mg u.i.d.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Switch from melatonin to agomelatine
Number of subjects: 62
Study: 23867888

Group type: EXPERIMENTAL
Intervention: Contralaterally controlled neuromuscular electrical stimulation (CCNMES)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cyclic neuromuscular electrical stimulation (NMES)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both CCNMES and cyclic NMES combined with gait training
Number of subjects: 26
Study: 20838215

Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg/d before bedtime)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 27950535

Group type: EXPERIMENTAL
Intervention: Erlotinib (E) 150 mg orally QD plus sulindac (S) 150 mg orally BID (Arm A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Erlotinib (E) 150 mg QD (Arm B)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo QD (Arm C)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Adjuvant Erlotinib (E) 150 mg QD for 2 years after postoperative chemoradiotherapy
Number of subjects: 85
Study: 16368840

Group type: EXPERIMENTAL
Intervention: Dexamethasone group (lidocaine 1.5% with 2 mL of dexamethasone 8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (lidocaine 1.5% with 2 mL of isotonic saline chloride)
Number of subjects: 60
Study: 14551182

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nefazodone titrated to a daily dose of 400 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluvoxamine titrated to a daily dose of 200 mg
Number of subjects: 40
Study: 10319663

Group type: EXPERIMENTAL
Intervention: Health promotion counseling from trained professional home care nurses
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional care (Control)
Number of subjects: 84
Study: 8731122

Group type: EXPERIMENTAL
Intervention: Intussuscepted ileal nipple valve
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stapled ileal ('Lundiana') outlet
Number of subjects: 30
Study: 1777912

Group type: COMPARATOR
Intervention: Ionic contrast agent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonionic contrast agent
Number of subjects: 12
Study: 7036376

Group type: EXPERIMENTAL
Intervention: Bicitropeptide powder
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3882108

Group type: EXPERIMENTAL
Intervention: sodium nitroprusside (SNP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: trimetaphan (TMP)
Number of subjects: 20
Study: 31357259

Group type: EXPERIMENTAL
Intervention: High-Intensity Group (HIG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low-Intensity Group (LIG)
Number of subjects: 62
Study: 29908775

Group type: EXPERIMENTAL
Intervention: Insulin resistance (measured by HOMA-IR)
Number of subjects: 738
Study: 27089205

Group type: EXPERIMENTAL
Intervention: TV003
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25424120

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Capecitabine plus oxaliplatin (CapeOX)
Number of subjects: 340
Study: 22945622

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Number of subjects: 36
Study: 19707823

Group type: COMPARATOR
Intervention: Ondansetron 4 mg (group O4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (group O8)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (group R)
Number of subjects: 120
Study: 18822983

Group type: EXPERIMENTAL
Intervention: Low energy He-Ne laser radiation at acupoints (CV 22, ST 9, CV 14, BL 12) for 5 days
Number of subjects: 255

Group type: COMPARATOR
Intervention: Oral administration of Amantadine tablets for 5 days
Number of subjects: 255
Study: 15702134

Group type: EXPERIMENTAL
Intervention: High-dose finasteride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11791151

Group type: EXPERIMENTAL
Intervention: Supervised exercise 5 days per week, 45 min per session, at 65% of heart rate reserve
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n=9)
Number of subjects: 27
Study: 10404019

Group type: COMPARATOR
Intervention: MK-677 10 mg for 2 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: MK-677 25 mg for 2 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: MK-677 25 mg daily for 2 weeks followed by 50 mg daily for 2 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: MK-677 (all groups combined) for 9 weeks
Number of subjects: 187
Study: 8567514

Group type: EXPERIMENTAL
Intervention: CHO+MCT trial (15% CHO solution + 29 g MCT suspension)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HCHO+MCT trial (high CHO (HCHO) 214 g + 29 g MCT suspension)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MCT trial (29 g MCT solution)
Number of subjects: 8
Study: 1963734

Group type: EXPERIMENTAL
Intervention: Cognitive coping, years of problem drinking
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early aftercare attendance
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Previous hospitalizations
Number of subjects: 39

Group type: COMPARATOR
Intervention: Demographics (age, marital status)
Number of subjects: 39
Study: 6993630

Group type: EXPERIMENTAL
Intervention: Frostig Program for the Development of Visual Perception
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (attention-placebo)
Number of subjects: 36
Study: 31260124

Group type: EXPERIMENTAL
Intervention: Tranilast 8% liposomal gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water-based placebo
Number of subjects: 40
Study: 31091343

Group type: EXPERIMENTAL
Intervention: Nursing care addressing patients' sleep
Number of subjects: 53

Group type: COMPARATOR
Intervention: Current training addressing sleep during hospital stay
Number of subjects: 53

Group type: COMPARATOR
Intervention: Policy documents regarding sleep management
Number of subjects: 53
Study: 28872752

Group type: EXPERIMENTAL
Intervention: 6 months supervised exercise followed by a 6-month home-based maintenance programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: Printed physical activity educational material for 12 months
Number of subjects: 100
Study: 27769191

Group type: EXPERIMENTAL
Intervention: Participatory Learning and Action (PLA)
Number of subjects: 8880

Group type: EXPERIMENTAL
Intervention: PLA plus food (10 kg of fortified sweetened wheat-soya Super Cereal per month)
Number of subjects: 8880

Group type: EXPERIMENTAL
Intervention: PLA plus cash (NPR 750 or US$7 per month)
Number of subjects: 8880

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 8880

Group type: EXPERIMENTAL
Intervention: All groups (PLA, PLA plus food, PLA plus cash, standard care)
Number of subjects: 8880